PDB Short entry for 2CJI HEADER HYDROLASE 03-APR-06 2CJI TITLE CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX COMPND MOL_ID: 1; COMPND 2 MOLECULE: ACTIVATED FACTOR XA HEAVY CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: ACTIVATED DESGLA, RESIDUES 235-488; COMPND 5 SYNONYM: COAGULATION FACTOR XA; COMPND 6 EC: 3.4.21.6; COMPND 7 OTHER_DETAILS: DISULPHIDE LINKED TO OTHER CHAIN; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: FACTOR X LIGHT CHAIN; COMPND 10 CHAIN: B; COMPND 11 FRAGMENT: ACTIVATED DESGLA, RESIDUES 46-179; COMPND 12 SYNONYM: COAGULATION FACTOR XA; COMPND 13 EC: 3.4.21.6; COMPND 14 OTHER_DETAILS: DISULPHIDE LINKED TO OTHER CHAIN SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 MOL_ID: 2; SOURCE 6 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 7 ORGANISM_COMMON: HUMAN; SOURCE 8 ORGANISM_TAXID: 9606 KEYWDS BLOOD COAGULATION, GAMMA-CARBOXYGLUTAMIC ACID, KEYWDS 2 HYDROXYLATION, EGF-LIKE DOMAIN, SERINE PROTEASE, CALCIUM, KEYWDS 3 ZYMOGEN, PROTEASE, HYDROLASE, GLYCOPROTEIN, POLYMORPHISM EXPDTA X-RAY DIFFRACTION AUTHOR N.S.WATSON,M.CAMPBELL,C.CHAN,M.A.CONVERY,J.N.HAMBLIN, AUTHOR 2 H.A.KELLY,N.P.KING,A.M.MASON,C.MITCHELL,V.K.PATEL,S.SENGER, AUTHOR 3 G.P.SHAH,H.E.WESTON,C.WHITWORTH,R.J.YOUNG REVDAT 3 24-FEB-09 2CJI 1 VERSN REVDAT 2 07-JUN-06 2CJI 1 JRNL REVDAT 1 17-MAY-06 2CJI 0 JRNL AUTH N.S.WATSON,D.BROWN,M.CAMPBELL,C.CHAN,L.CHAUDRY, JRNL AUTH 2 M.A.CONVERY,R.FENWICK,J.N.HAMBLIN,C.HASLAM, JRNL AUTH 3 H.A.KELLY,N.P.KING,C.L.KURTIS,A.R.LEACH, JRNL AUTH 4 G.R.MANCHEE,A.M.MASON,C.MITCHELL,C.PATEL,V.K.PATEL, JRNL AUTH 5 S.SENGER,G.P.SHAH,H.E.WESTON,C.WHITWORTH,R.J.YOUNG JRNL TITL DESIGN AND SYNTHESIS OF ORALLY ACTIVE PYRROLIDIN- JRNL TITL 2 2-ONE-BASED FACTOR XA INHIBITORS JRNL REF BIOORG.MED.CHEM.LETT. V. 16 3784 2006 JRNL REFN ISSN 0960-894X JRNL PMID 16697194 JRNL DOI 10.1016/J.BMCL.2006.04.053 REMARK 2 REMARK 2 RESOLUTION. 2.1 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0005 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 3 NUMBER OF REFLECTIONS : 18829 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.195 REMARK 3 R VALUE (WORKING SET) : 0.192 REMARK 3 FREE R VALUE : 0.242 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1015 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.10 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.15 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1335 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2420 REMARK 3 BIN FREE R VALUE SET COUNT : 68 REMARK 3 BIN FREE R VALUE : 0.2980 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2148 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 32 REMARK 3 SOLVENT ATOMS : 143 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 32.68 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.43000 REMARK 3 B22 (A**2) : -1.69000 REMARK 3 B33 (A**2) : 1.26000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.203 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.182 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.137 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 5.152 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.951 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.920 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2237 ; 0.016 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3032 ; 1.580 ; 1.960 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 284 ; 3.980 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 92 ;27.406 ;23.913 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 348 ;11.103 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 12 ;17.578 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 332 ; 0.112 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 1693 ; 0.006 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 818 ; 0.207 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 1505 ; 0.306 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 122 ; 0.147 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 13 ; 0.258 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 16 ; 0.144 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1466 ; 1.723 ; 2.000 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2249 ; 2.825 ; 4.000 REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 929 ; 3.851 ; 5.000 REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 783 ; 5.120 ; 7.000 REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE REMARK 3 RIDING POSITIONS. REMARK 4 REMARK 4 2CJI COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 04-APR-06. REMARK 100 THE PDBE ID CODE IS EBI-28356. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 28-MAR-01 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 5.75 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SRS REMARK 200 BEAMLINE : PX9.6 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.87 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19989 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.100 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 4.040 REMARK 200 R MERGE (I) : 0.08000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.10 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.18 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.53000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: SEE REMARK REMARK 200 REMARK 200 REMARK: 1EZQ WAS USED AS STARTING MODEL FOR REFINEMENT REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 49.43 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.45 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 18% PEG 6K, 100MM MES PH5.75, REMARK 280 10MM CACL2 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.48400 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 39.89200 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.31650 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 39.89200 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.48400 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 36.31650 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 GENERATING THE BIOMOLECULE REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 FACTOR XA IS A VITAMIN K-DEPENDENT GLYCOPROTEIN THAT REMARK 400 CONVERTS PROTHROMBIN TO THROMBIN IN THE PRESENCE OF FACTOR REMARK 400 VA, CALCIUM AND PHOSPHOLIPID DURING BLOOD CLOTTING REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ARG A 245 REMARK 465 GLY A 246 REMARK 465 LEU A 247 REMARK 465 PRO A 248 REMARK 465 LYS A 249 REMARK 465 ALA A 250 REMARK 465 LYS A 251 REMARK 465 SER A 252 REMARK 465 HIS A 253 REMARK 465 ALA A 254 REMARK 465 PRO A 255 REMARK 465 GLU A 256 REMARK 465 VAL A 257 REMARK 465 ILE A 258 REMARK 465 THR A 259 REMARK 465 SER A 260 REMARK 465 SER A 261 REMARK 465 PRO A 262 REMARK 465 LEU A 263 REMARK 465 LYS A 264 REMARK 465 GLU B -82 REMARK 465 GLU B -81 REMARK 465 MET B -80 REMARK 465 LYS B -79 REMARK 465 LYS B -78 REMARK 465 GLY B -77 REMARK 465 HIS B -76 REMARK 465 LEU B -75 REMARK 465 GLU B -74 REMARK 465 ARG B -73 REMARK 465 GLU B -72 REMARK 465 CYS B -71 REMARK 465 MET B -70 REMARK 465 GLU B -69 REMARK 465 GLU B -68 REMARK 465 THR B -67 REMARK 465 CYS B -66 REMARK 465 SER B -65 REMARK 465 TYR B -64 REMARK 465 GLU B -63 REMARK 465 GLU B -62 REMARK 465 ALA B -61 REMARK 465 ARG B -60 REMARK 465 GLU B -59 REMARK 465 VAL B -58 REMARK 465 PHE B -57 REMARK 465 GLU B -56 REMARK 465 ASP B -55 REMARK 465 SER B -54 REMARK 465 ASP B -53 REMARK 465 LYS B -52 REMARK 465 THR B -51 REMARK 465 ASN B -50 REMARK 465 GLU B -49 REMARK 465 PHE B -48 REMARK 465 TRP B -47 REMARK 465 ASN B -46 REMARK 465 LYS B -45 REMARK 465 TYR B -44 REMARK 465 LYS B -43 REMARK 465 ASP B -42 REMARK 465 GLY B -41 REMARK 465 ASP B -40 REMARK 465 GLN B -39 REMARK 465 CYS B -38 REMARK 465 GLU B -37 REMARK 465 THR B -36 REMARK 465 SER B -35 REMARK 465 PRO B -34 REMARK 465 CYS B -33 REMARK 465 GLN B -32 REMARK 465 ASN B -31 REMARK 465 GLN B -30 REMARK 465 GLY B -29 REMARK 465 LYS B -28 REMARK 465 CYS B -27 REMARK 465 LYS B -26 REMARK 465 ASP B -25 REMARK 465 GLY B -24 REMARK 465 LEU B -23 REMARK 465 GLY B -22 REMARK 465 GLU B -21 REMARK 465 TYR B -20 REMARK 465 THR B -19 REMARK 465 CYS B -18 REMARK 465 THR B -17 REMARK 465 CYS B -16 REMARK 465 LEU B -15 REMARK 465 GLU B -14 REMARK 465 GLY B -13 REMARK 465 PHE B -12 REMARK 465 GLU B -11 REMARK 465 GLY B -10 REMARK 465 LYS B -9 REMARK 465 ASN B -8 REMARK 465 CYS B -7 REMARK 465 GLU B -6 REMARK 465 LEU B -5 REMARK 465 PHE B -4 REMARK 465 THR B -3 REMARK 465 ARG B -2 REMARK 465 ARG B 51 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 36 CD OE1 OE2 REMARK 470 GLU A 37 CG CD OE1 OE2 REMARK 470 GLU A 39 CG CD OE1 OE2 REMARK 470 GLN A 61 CD OE1 NE2 REMARK 470 LYS A 62 CB CG CD CE NZ REMARK 470 ARG A 63 CG CD NE CZ NH1 NH2 REMARK 470 GLU A 76 CG CD OE1 OE2 REMARK 470 GLU A 77 CG CD OE1 OE2 REMARK 470 LYS A 96 CG CD CE NZ REMARK 470 GLU A 97 CD OE1 OE2 REMARK 470 LYS A 134 CD CE NZ REMARK 470 LYS A 148 CG CD CE NZ REMARK 470 ARG A 150 CD NE CZ NH1 NH2 REMARK 470 GLN A 187 CD OE1 NE2 REMARK 470 LYS A 223 CG CD CE NZ REMARK 470 LYS A 243 CG CD CE NZ REMARK 470 THR A 244 OG1 CG2 REMARK 470 LYS B -1 CG CD CE NZ REMARK 470 HIS B 13 CG ND1 CD2 CE1 NE2 REMARK 470 GLU B 15 CD OE1 OE2 REMARK 470 GLN B 16 CG CD OE1 NE2 REMARK 470 ASN B 17 CG OD1 ND2 REMARK 470 ARG B 25 NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 48 -179.60 -175.19 REMARK 500 THR A 73 4.58 -69.88 REMARK 500 ARG A 115 -169.78 -176.58 REMARK 500 LEU B 0 -122.11 49.35 REMARK 500 GLN B 10 -114.97 -127.66 REMARK 500 GLN B 16 74.37 45.09 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 CA A1245 CA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HOH A2024 O REMARK 620 2 ASN A 72 O 90.0 REMARK 620 3 GLN A 75 O 95.9 86.9 REMARK 620 4 ASP A 70 OD1 77.8 92.0 173.5 REMARK 620 5 HOH A2023 O 153.9 83.9 109.0 77.2 REMARK 620 6 GLU A 80 OE1 99.2 170.7 90.3 91.8 88.7 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CA A1245 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GSK A1246 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1C5M RELATED DB: PDB REMARK 900 STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL REMARK 900 MOLECULE, S1-BINDING, SUB- MICROMOLAR REMARK 900 INHIBITOR OF UROKINASE TYPE PLASMINOGEN REMARK 900 ACTIVATOR REMARK 900 RELATED ID: 1EZQ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR REMARK 900 XA COMPLEXED WITH RPR128515 REMARK 900 RELATED ID: 1F0R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR REMARK 900 XA COMPLEXED WITH RPR208815 REMARK 900 RELATED ID: 1F0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR REMARK 900 XA COMPLEXED WITH RPR208707 REMARK 900 RELATED ID: 1FAX RELATED DB: PDB REMARK 900 COAGULATION FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1FJS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 REMARK 900 (CI-1031)COMPLEXED WITH FACTOR XA REMARK 900 RELATED ID: 1FXY RELATED DB: PDB REMARK 900 COAGULATION FACTOR XA-TRYPSIN CHIMERA REMARK 900 INHIBITED WITH D-PHE-PRO-ARG- REMARK 900 CHLOROMETHYLKETONE REMARK 900 RELATED ID: 1G2L RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1G2M RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1HCG RELATED DB: PDB REMARK 900 BLOOD COAGULATION FACTOR XA REMARK 900 RELATED ID: 1IOE RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M55532 REMARK 900 RELATED ID: 1IQE RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M55590 REMARK 900 RELATED ID: 1IQF RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M55165 REMARK 900 RELATED ID: 1IQG RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M55159 REMARK 900 RELATED ID: 1IQH RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M55143 REMARK 900 RELATED ID: 1IQI RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M55125 REMARK 900 RELATED ID: 1IQJ RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M55124 REMARK 900 RELATED ID: 1IQK RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M55113 REMARK 900 RELATED ID: 1IQL RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M54476 REMARK 900 RELATED ID: 1IQM RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M54471 REMARK 900 RELATED ID: 1IQN RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH REMARK 900 M55192 REMARK 900 RELATED ID: 1KSN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR REMARK 900 XA COMPLEXEDWITH FXV673 REMARK 900 RELATED ID: 1KYE RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH (R)-2-(3- REMARK 900 ADAMANTAN-1-YL-UREIDO)-3-(3-CARBAMIMIDOYL- REMARK 900 PHENYL)-N-PHENETHYL-PROPIONAMIDE REMARK 900 RELATED ID: 1LPG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH REMARK 900 79. REMARK 900 RELATED ID: 1LPK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH REMARK 900 125. REMARK 900 RELATED ID: 1LPZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH REMARK 900 41. REMARK 900 RELATED ID: 1LQD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH REMARK 900 45. REMARK 900 RELATED ID: 1MQ5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO REMARK 900 -2-[[(4-CHLOROPHENYL)AMINO]CARBONYL]PHENYL]- REMARK 900 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2- REMARK 900 THIOPHENECARBOXAMIDE COMPLEXED WITHHUMAN FACTOR REMARK 900 XA REMARK 900 RELATED ID: 1MQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO REMARK 900 -2-[[(5-CHLORO-2-PYRIDINYL)AMINO]CARBONYL REMARK 900 ]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2- REMARK 900 OXAZOLYL)METHYLAMINO]METHYL]-2- REMARK 900 THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR REMARK 900 XA REMARK 900 RELATED ID: 1MSX RELATED DB: PDB REMARK 900 HUMAN FACTOR XA COMPLEXED WITH 2-[3-(15N- REMARK 900 AMINO-15N-IMINO-13C-METHYL)PHENOXY]-6-[3 REMARK 900 -(15N-AMINO-13C-METHYL)PHENOXY]-3,5- REMARK 900 DIFLUORO-4-METHYLPYRIDINE (ZK-806299), BINDING REMARK 900 MODELFROM DOUBLE REDOR NMR AND MD REMARK 900 SIMULATIONS. REMARK 900 RELATED ID: 1NFU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR REMARK 900 XA COMPLEXEDWITH RPR132747 REMARK 900 RELATED ID: 1NFW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR REMARK 900 XA COMPLEXEDWITH RPR209685 REMARK 900 RELATED ID: 1NFX RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR REMARK 900 XA COMPLEXEDWITH RPR208944 REMARK 900 RELATED ID: 1NFY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR REMARK 900 XA COMPLEXEDWITH RPR200095 REMARK 900 RELATED ID: 1NL8 RELATED DB: PDB REMARK 900 THEORETICAL MODEL OF THE TISSUE FACTOR/ REMARK 900 FACTOR VIIA/FACTORXA COMPLEX REMARK 900 RELATED ID: 1P0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR REMARK 900 XA IN COMPLEXWITH ECOTIN M84R REMARK 900 RELATED ID: 1V3X RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 REMARK 900 -[6-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO(5, REMARK 900 4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4 REMARK 900 -(6-CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE REMARK 900 RELATED ID: 1WU1 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 4 REMARK 900 -[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2- REMARK 900 METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN REMARK 900 -2-YL]CARBONYL]PIPERAZINE REMARK 900 RELATED ID: 1XKA RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC REMARK 900 INHIBITOR FX-2212A,(2S) -(3'-AMIDINO-3- REMARK 900 BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 1XKB RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC REMARK 900 INHIBITOR FX-2212A,(2S) -(3'-AMIDINO-3- REMARK 900 BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 1Z6E RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA COMPLEXED TO REMARK 900 RAZAXABAN REMARK 900 RELATED ID: 2BMG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX REMARK 900 WITH 50 REMARK 900 RELATED ID: 2BOH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX REMARK 900 WITH 1 REMARK 900 RELATED ID: 2BOK RELATED DB: PDB REMARK 900 FACTOR XA - CATION REMARK 900 RELATED ID: 2BQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX REMARK 900 WITH 21 REMARK 900 RELATED ID: 2BQ7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX REMARK 900 WITH 43 REMARK 900 RELATED ID: 2BQW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX REMARK 900 WITH COMPOUND 45 REMARK 900 RELATED ID: 2GD4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A REMARK 900 FACTOR XA-PENTASACCHARIDE COMPLEX REMARK 999 REMARK 999 SEQUENCE REMARK 999 SOME RESIDUES IN CHAIN ARE NOT SEEN IN THE ELECTRON REMARK 999 DENSITY. SEQUENCE DATABASE RESIDUES 1-45 (THE GLA DOMAIN) REMARK 999 WERE BIOCHEMICALLY REMOVED IN CHAIN B DBREF 2CJI A 16 145 UNP P00742 FA10_HUMAN 235 368 DBREF 2CJI A 147 217 UNP P00742 FA10_HUMAN 369 441 DBREF 2CJI A 219 264 UNP P00742 FA10_HUMAN 442 488 DBREF 2CJI B -82 51 UNP P00742 FA10_HUMAN 46 179 SEQRES 1 A 254 ILE VAL GLY GLY GLN GLU CYS LYS ASP GLY GLU CYS PRO SEQRES 2 A 254 TRP GLN ALA LEU LEU ILE ASN GLU GLU ASN GLU GLY PHE SEQRES 3 A 254 CYS GLY GLY THR ILE LEU SER GLU PHE TYR ILE LEU THR SEQRES 4 A 254 ALA ALA HIS CYS LEU TYR GLN ALA LYS ARG PHE LYS VAL SEQRES 5 A 254 ARG VAL GLY ASP ARG ASN THR GLU GLN GLU GLU GLY GLY SEQRES 6 A 254 GLU ALA VAL HIS GLU VAL GLU VAL VAL ILE LYS HIS ASN SEQRES 7 A 254 ARG PHE THR LYS GLU THR TYR ASP PHE ASP ILE ALA VAL SEQRES 8 A 254 LEU ARG LEU LYS THR PRO ILE THR PHE ARG MET ASN VAL SEQRES 9 A 254 ALA PRO ALA CYS LEU PRO GLU ARG ASP TRP ALA GLU SER SEQRES 10 A 254 THR LEU MET THR GLN LYS THR GLY ILE VAL SER GLY PHE SEQRES 11 A 254 GLY ARG THR HIS GLU LYS GLY ARG GLN SER THR ARG LEU SEQRES 12 A 254 LYS MET LEU GLU VAL PRO TYR VAL ASP ARG ASN SER CYS SEQRES 13 A 254 LYS LEU SER SER SER PHE ILE ILE THR GLN ASN MET PHE SEQRES 14 A 254 CYS ALA GLY TYR ASP THR LYS GLN GLU ASP ALA CYS GLN SEQRES 15 A 254 GLY ASP SER GLY GLY PRO HIS VAL THR ARG PHE LYS ASP SEQRES 16 A 254 THR TYR PHE VAL THR GLY ILE VAL SER TRP GLY GLU GLY SEQRES 17 A 254 CYS ALA ARG LYS GLY LYS TYR GLY ILE TYR THR LYS VAL SEQRES 18 A 254 THR ALA PHE LEU LYS TRP ILE ASP ARG SER MET LYS THR SEQRES 19 A 254 ARG GLY LEU PRO LYS ALA LYS SER HIS ALA PRO GLU VAL SEQRES 20 A 254 ILE THR SER SER PRO LEU LYS SEQRES 1 B 134 GLU GLU MET LYS LYS GLY HIS LEU GLU ARG GLU CYS MET SEQRES 2 B 134 GLU GLU THR CYS SER TYR GLU GLU ALA ARG GLU VAL PHE SEQRES 3 B 134 GLU ASP SER ASP LYS THR ASN GLU PHE TRP ASN LYS TYR SEQRES 4 B 134 LYS ASP GLY ASP GLN CYS GLU THR SER PRO CYS GLN ASN SEQRES 5 B 134 GLN GLY LYS CYS LYS ASP GLY LEU GLY GLU TYR THR CYS SEQRES 6 B 134 THR CYS LEU GLU GLY PHE GLU GLY LYS ASN CYS GLU LEU SEQRES 7 B 134 PHE THR ARG LYS LEU CYS SER LEU ASP ASN GLY ASP CYS SEQRES 8 B 134 ASP GLN PHE CYS HIS GLU GLU GLN ASN SER VAL VAL CYS SEQRES 9 B 134 SER CYS ALA ARG GLY TYR THR LEU ALA ASP ASN GLY LYS SEQRES 10 B 134 ALA CYS ILE PRO THR GLY PRO TYR PRO CYS GLY LYS GLN SEQRES 11 B 134 THR LEU GLU ARG HET CA A1245 1 HET GSK A1246 31 HETNAM CA CALCIUM ION HETNAM GSK 6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-(4- HETNAM 2 GSK MORPHOLINYL)-2-OXO ETHYL]-2-OXO-3-PYRROLIDINYL}-2- HETNAM 3 GSK NAPHTHALENESULFONAMIDE FORMUL 3 CA CA 2+ FORMUL 4 GSK C21 H24 CL N3 O5 S FORMUL 5 HOH *143(H2 O1) HELIX 1 1 ALA A 55 GLN A 61 5 7 HELIX 2 2 ARG A 125 LEU A 131A 1 8 HELIX 3 3 ASP A 164 SER A 172 1 9 HELIX 4 4 PHE A 234 THR A 244 1 11 HELIX 5 5 LYS B -1 LEU B 3 5 5 HELIX 6 6 LEU B 3 CYS B 8 5 6 SHEET 1 AA 7 GLN A 20 GLU A 21 0 SHEET 2 AA 7 LYS A 156 PRO A 161 -1 O MET A 157 N GLN A 20 SHEET 3 AA 7 THR A 135 GLY A 140 -1 O GLY A 136 N VAL A 160 SHEET 4 AA 7 PRO A 198 PHE A 203 -1 O PRO A 198 N SER A 139 SHEET 5 AA 7 THR A 206 TRP A 215 -1 O THR A 206 N PHE A 203 SHEET 6 AA 7 GLY A 226 LYS A 230 -1 O ILE A 227 N TRP A 215 SHEET 7 AA 7 MET A 180 ALA A 183 -1 O PHE A 181 N TYR A 228 SHEET 1 AB 7 ALA A 81 HIS A 83 0 SHEET 2 AB 7 LYS A 65 VAL A 68 -1 O VAL A 66 N HIS A 83 SHEET 3 AB 7 GLN A 30 ILE A 34 -1 O LEU A 32 N ARG A 67 SHEET 4 AB 7 GLY A 40 ILE A 46 -1 N PHE A 41 O LEU A 33 SHEET 5 AB 7 TYR A 51 THR A 54 -1 O LEU A 53 N THR A 45 SHEET 6 AB 7 ALA A 104 LEU A 108 -1 O ALA A 104 N THR A 54 SHEET 7 AB 7 VAL A 85 LYS A 90 -1 N GLU A 86 O ARG A 107 SHEET 1 BA 2 PHE B 11 GLU B 14 0 SHEET 2 BA 2 VAL B 19 SER B 22 -1 O VAL B 20 N HIS B 13 SHEET 1 BB 2 TYR B 27 LEU B 29 0 SHEET 2 BB 2 CYS B 36 PRO B 38 -1 O ILE B 37 N THR B 28 SSBOND 1 CYS A 22 CYS A 27 1555 1555 2.04 SSBOND 2 CYS A 42 CYS A 58 1555 1555 2.01 SSBOND 3 CYS A 122 CYS B 44 1555 1555 2.05 SSBOND 4 CYS A 168 CYS A 182 1555 1555 1.98 SSBOND 5 CYS A 191 CYS A 220 1555 1555 2.06 SSBOND 6 CYS B 1 CYS B 12 1555 1555 2.07 SSBOND 7 CYS B 8 CYS B 21 1555 1555 2.03 SSBOND 8 CYS B 23 CYS B 36 1555 1555 2.06 LINK CA CA A1245 O HOH A2024 1555 1555 2.67 LINK CA CA A1245 O ASN A 72 1555 1555 2.32 LINK CA CA A1245 O GLN A 75 1555 1555 2.31 LINK CA CA A1245 OD1 ASP A 70 1555 1555 2.32 LINK CA CA A1245 O HOH A2023 1555 1555 2.33 LINK CA CA A1245 OE1 GLU A 80 1555 1555 2.32 SITE 1 AC1 6 ASP A 70 ASN A 72 GLN A 75 GLU A 80 SITE 2 AC1 6 HOH A2023 HOH A2024 SITE 1 AC2 15 GLU A 97 THR A 98 PHE A 174 ALA A 190 SITE 2 AC2 15 GLN A 192 SER A 195 VAL A 213 TRP A 215 SITE 3 AC2 15 GLY A 216 GLY A 219 CYS A 220 GLY A 226 SITE 4 AC2 15 ILE A 227 TYR A 228 HOH A2099 CRYST1 56.968 72.633 79.784 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017554 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013768 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012534 0.00000